Abstract
The aim of this study was to determine the role of pregnane X receptor (PXR) in the induction of UDP-glucuronosyltransferases (UGTs) by pregnenolone-16α-carbonitrile (PCN). Four- to six-month-old male wild-type and PXR-null mice received control or PCN-treated (1500 ppm) diet for 21 days. On day 22, livers were taken to prepare microsomes and total RNA to determine UGT activity and mRNA levels, respectively. In wild-type mice, PCN treatment significantly increased UGT activities toward bilirubin, 1-naphthol, chloramphenicol, thyroxine, and triiodothyronine. On control diet, the UGT activities toward the above substrates (except for 1-naphthol) in the PXR-null mice were significantly higher than those of wild-type mice. However, UGT activities in PXR-null mice were not increased by PCN. In agreement with the above findings, mRNA levels of mouse Ugt1a1 and Ugt1a9, which are involved in the glucuronidation of bilirubin and phenolic compounds, were increased about 100% in wild-type mice following PCN treatment, whereas the expression of Ugt1a2, 1a6, and 2b5 was not affected. In contrast, PCN treatment had no effect on the mRNA levels of these UGTs in PXR-null mice. Taken together, these results indicate that PCN treatment induces glucuronidation in mouse liver, and that PXR regulates constitutive and PCN-inducible expression of some UGTs.
Footnotes
-
↵1 Current address: Department of Pharmacology and Toxicology, University of Kansas, Lawrence, KS 66045.
-
↵2 Abbreviations used are: T4, thyroxine; T3, triiodothyronine; UGTs, UDP-glucuronosyltransferases; MEIs, microsomal enzyme inducers; 3-MC, 3-methylcholanthrene; PB, phenobarbital; PCN, pregnenolone-16α-carbonitrile; CAR, constitutive androstane receptor; PXR, pregnane X receptor; RXR, 9-cis retinoic acid receptor; GA, glucuronic acid; CHAPS, 3-[(3-chlolamidopropyl) dimethylammonio]-1-propanesulfonic acid; TSH, thyroid stimulating hormone; UGTs, UDP-glucuronosyltransferases.
-
This work was supported by National Institutes of Health Grant ES-08156 to Curtis D. Klaassen.
- Received January 7, 2003.
- Accepted March 25, 2003.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|